Immunogenicity of a new Salmonella Typhi Vi polysaccharide vaccine—vax-TyVi ®—in Cuban school children and teenagers

A randomized, controlled, double blind study was carried out in Cuban children and teenagers aged 9–13 years to evaluate the immunogenicity of vax-TyVi ®— Salmonella Typhi Vi polysaccharide vaccine—with respect control vaccines. Serum samples were taken before and 21 days after the immunization, and ELISA was used for the determination of antibodies to Vi polysaccharide. Subjects who received vax-TyVi ® and TYPHIM Vi™ (Pasteur-Mérieux) showed seroconversion rates of 85.61 and 78.36%, respectively. The geometric mean titer (GMT) values for Vi antibodies induced after vaccination were 6.27 μg/ml (5.40–7.38 μg/ml) and 5.97 μg/ml (5.01–7.10 μg/ml), respectively. In contrast, subjects receiving the tetanus toxoid vaccine showed 0% seroconversion.